"One of Welch Allyn's top priorities is to bring patient monitoring to the presently unmonitored bed, which makes up over eighty percent of today's hospital beds," added Linquest. "These beds are typically general care or medical-surgical beds and require advanced and connected spot-check vital signs devices. The new Propaq LT monitor effectively bridges the gap (cost, size and complexity) between today's continuous patient monitors and spot-check devices like Spot Vital Signs that offer even more comprehensive clinical benefits to the unmonitored bed."

"This partnership confirms the strength of our business relationship with Welch Allyn and the commitment of both companies to bring best in class patient monitoring technology to new clinical sites," said Joe E. Kiani, Chairman and CEO of Masimo Corporation. "We are happy that by partnering with Welch Allyn, we can offer the proven benefits of Masimo SET pulse oximetry to more clinicians and patients in more diverse clinical settings."


For more information about Welch Allyn vital signs capture and monitoring devices, visit www.welchallyn.com.

Back to HCB News

More Voices